Regeneus provides the Company’s Presentation on Japan First Strategy at Ord Minnett.
Sydney, Nov 1, 2017 - (ABN Newswire) - Regeneus (ASX:RGS) provides the Company’s Presentation on Japan First Strategy at Ord Minnett.
Company Snapshot
3 world class-technology platforms
- Allogeneic adult stem cells (MSCs) from adipose tissue for osteoarthritis and other inflammatory conditions (Progenza, CryoShot)
- Immuno-therapy for oncology (RGSH4K, Kvax)
- Cell-free secretions from MSCs focused on dermatology and inflammatory skin conditions (Sygenus)
Diversified portfolio of clinical stage products
- Human and animal health markets
- Multiple product opportunities addressing multiple significant unmet medical needs - many shots on goal
- Technology supported by emerging positive clinical data
- Scalable manufacturing for allogeneic stem cells
- IP portfolio underpins technology and product pipeline for wide range of inflammatory indications
- Licence driven business model
Driven by innovation and collaboration
- Track record of technology innovation and rapid translation to the clinic
- Successful technology and clinical collaborations (AGC, Kolling Institute, Macquarie and Adelaide Unis)
- Experienced and commercially focused management team and Board
- Well positioned to unlock significant value over next 12 months
Japan First Strategy
- Most Australian biotechs seek to license for US and EU markets first
- Japan first strategy takes advantage of globally attractive market conditions
o fast-track regulatory environment for RM products
-- shorter phase 2 trial - “probable efficacy”
-- Conditional Approval 5-7 years means no requirement for phase 3
-- can commercialise product during CA phase
-- 70% government reimbursement includes CA phase
o supportive regulator - PMDA and government departments
o high level of industry engagement for market sector - FIRM >250 members
- Focus on product manufacturing and standardization allows for separating manufacturing and clinical licensing transactions
- Licensees willing to do Japan only transactions - benchmarks marks value and leaves other territories available
- Japan can validate opportunity for other markets
- Other jurisdictions influenced by new regulatory framework - eg South Korea and USA
To view the presentation, please visit:
http://abnnewswire.net/lnk/RQX8AES4
